prikaz prve stranice dokumenta Changes in haemostasis and inflammatory markers after mRNA BNT162b2 and vector Ad26.CoV2.S SARS-CoV-2 vaccination
  Preuzmi
PDF 412.17 KB
Znanstveni rad - Izvorni znanstveni rad
Changes in haemostasis and inflammatory markers after mRNA BNT162b2 and vector Ad26.CoV2.S SARS-CoV-2 vaccination
Thrombosis Research, 228 (2023); 137-144. https://doi.org/10.1016/j.thromres.2023.06.008
Ivanko, I.; Ćelap, I.; Margetić, S.; Marijančević, D.; Josipović, J.; Gaćina, P.

Citirajte ovaj rad

Ivanko, I., Ćelap, I., Margetić, S., Marijančević, D., Josipović, J. i Gaćina, P. (2023). Changes in haemostasis and inflammatory markers after mRNA BNT162b2 and vector Ad26.CoV2.S SARS-CoV-2 vaccination. Thrombosis Research, 228., 137-144. doi: 10.1016/j.thromres.2023.06.008

Ivanko, I., et al. "Changes in haemostasis and inflammatory markers after mRNA BNT162b2 and vector Ad26.CoV2.S SARS-CoV-2 vaccination." Thrombosis Research, vol. 228, 2023, str. 137-144. https://doi.org/10.1016/j.thromres.2023.06.008

Ivanko, I., I. Ćelap, S. Margetić, D. Marijančević, J. Josipović i P. Gaćina. "Changes in haemostasis and inflammatory markers after mRNA BNT162b2 and vector Ad26.CoV2.S SARS-CoV-2 vaccination." Thrombosis Research 228 (2023): 137-144. https://doi.org/10.1016/j.thromres.2023.06.008

Ivanko, I., et al. (2023) 'Changes in haemostasis and inflammatory markers after mRNA BNT162b2 and vector Ad26.CoV2.S SARS-CoV-2 vaccination', Thrombosis Research, 228, str. 137-144. doi: 10.1016/j.thromres.2023.06.008

Ivanko I, Ćelap I, Margetić S, Marijančević D, Josipović J, Gaćina P. Changes in haemostasis and inflammatory markers after mRNA BNT162b2 and vector Ad26.CoV2.S SARS-CoV-2 vaccination. Thrombosis Research [Internet]. 08.2023. [pristupljeno 06.12.2024.];228:137-144. doi: 10.1016/j.thromres.2023.06.008

I. Ivanko, I. Ćelap, S. Margetić, D. Marijančević, J. Josipović i P. Gaćina, "Changes in haemostasis and inflammatory markers after mRNA BNT162b2 and vector Ad26.CoV2.S SARS-CoV-2 vaccination", Thrombosis Research, vol. 228, str. 137-144, Kolovoz 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:127:198802. [Citirano: 06.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:127:198802
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Changes in haemostasis and inflammatory markers after mRNA BNT162b2 and vector Ad26.CoV2.S SARS-CoV-2 vaccination
AutorI. Ivanko
AutorI. Ćelap
AutorS. Margetić
AutorD. Marijančević
AutorJ. Josipović
AutorP. Gaćina
Autorova ustanovaHrvatsko katoličko sveučilište
Autorova ustanova(Klinički bolnički centar Sestre milosrdnice)
Autorova ustanovaSveučilište u Zagrebu
Stomatološki fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Dentalna medicina
Sažetak (engleski)
Introduction: Reported thromboembolic events after SARS-CoV-2 vaccinations are still raising concerns, predominantly in non-scientific population. The aim of our study was to investigate the differences between haemostasis and inflammatory markers in the subjects vaccinated with mRNA BNT162b2 and vector Ad26.CoV2.S vaccine. Materials and methods: The study included 87 subjects vaccinated with mRNA BNT162b2 and 84 with Ad26. CoV2.S vaccine. All the laboratory parameters (TAT, F 1 + 2, IL-6, CRP, big endothelin-1, platelets, fibrinogen, Ddimers, VWF activity) were investigated for the mRNA vaccine at five (before the first dose, 7 and 14 days after the first and second vaccine dose), and three time points (before the first dose, 7 and 14 days after) for the vector vaccine, respectively. All the markers were measured by well-established laboratory methods. Results: Our results have shown statistically higher CRP levels in the vector group 7 days after vaccination (P = 0.014). Furthermore, study has revealed statistically significant rise in D-dimers (P = 0.004) between tested time points in both vaccine groups but without clinical repercussions. Conclusion: Although statistically significant changes in haemostasis markers have been obtained, they remained clinically irrelevant. Thus, our study implicates that there is no plausible scientific evidence of a significant disruption in the coagulation and inflammatory processes after vaccination with BNT162b2 mRNA and Ad26. CoV2.S vector SARS-CoV-2 vaccines.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaThrombosis Research
Brojčani podacivol. 228, str. 137-144
p-ISSN0049-3848
DOIhttps://doi.org/10.1016/j.thromres.2023.06.008
URN:NBNurn:nbn:hr:127:198802
Datum objave publikacije2023-08
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S0049384823001809
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-10-21 10:47:53